SCYNEXIS
SCYX | NASDAQ
$2.91
-$0.30 (-9.35%)
At close: Nov 16, 2026, 4:00 PM ET
$2.90
-$0.01 (-0.34%)
After-hours:
Nov 16, 2026, 7:30 PM ET
SCYNEXIS Company Profile
Company profile explainedCompany Profile
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Key Executives
| Name | Position |
|---|---|
| David Gonzalez Angulo | Chief Executive Officer, President & Director |
| Sanjay S. Subramanian | Chief Financial Officer |
| Scott Sukenick | Chief Legal Officer & Corporate Secretary |
| Daniella Gigante | Vice President of Human Resources & Information Technology |
| Ivor Macleod | Executive Officer |
| Todd Minga | Senior Vice President of Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 28, 2026 | 8-K | Current Report |
| Sep 22, 2026 | 4 | Filing |
| Sep 22, 2026 | 3 | Filing |
| Sep 22, 2026 | 8-K | Current Report |
| Sep 11, 2026 | 4 | Filing |
| Sep 11, 2026 | 3 | Filing |
| Sep 10, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
SCYNEXIS
| Country | United States |
| IPO Date | May 2, 2014 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 18 |
| CEO | David Angulo |
Contact Details
1 Evertrust Plaza Jersey City,
New Jersey 07302-6548 United States
Stock Details
| Ticker Symbol | SCYX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001178253 |
| CUSIP Number | 811292309 |
| ISIN Number | US8112923094 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove SCYX